Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase

Simply Wall St.03-20

AdvertisementInstitutional buying sparks new attention on MoonLake Immunotherapeutics Cormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620738974?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-20 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620738974","market":"us","top_or_hot":-1,"title":"Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementInstitutional buying sparks new attention on MoonLake Immunotherapeutics Cormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementInstitutional buying sparks new attention on MoonLake Immunotherapeutics Cormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c","article_id":"2620738974","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620738974","pubTimestamp":1774004859,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Institutional buying sparks new attention on MoonLake Immunotherapeutics\nCormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics (NasdaqCM:MLTX) shares for an estimated US$27.86 million, has put the clinical stage biotech back on investor watchlists.\nSee our latest analysis for MoonLake Immunotherapeutics.\nMoonLake’s recent 2.8% 1 day share price return to US$16.68 comes after a sharp sell off last year, with a 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics","BK4139":"生物科技"},"translate_title":"Cormorant大量股票购买后评估MoonLake Immunotherapeutics(MLTX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1.5},"content_text":"AdvertisementInstitutional buying sparks new attention on MoonLake Immunotherapeutics Cormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics (NasdaqCM:MLTX) shares for an estimated US$27.86 million, has put the clinical stage biotech back on investor watchlists. See our latest analysis for MoonLake Immunotherapeutics. MoonLake’s recent 2.8% 1 day share price return to US$16.68 comes after a sharp sell off last year, with a 1 year total shareholder return of a 59% loss despite a 39.6% year to date share price gain and 64.2% 5 year total shareholder return. This points to improving near term momentum as investors reassess the clinical story following Cormorant’s purchase and earlier trial volatility. If this kind of renewed interest in biotech catches your eye, it can be useful to see how other healthcare names are trading too. A good place to start is 35 healthcare AI stocks With MoonLake still down 59% over 1 year, yet up 39.6% year to date and trading at a roughly 45% discount to the average analyst price target of US$25.86, are you looking at a reset entry point or a market already pricing in future growth? Preferred price to book multiple of 3.9x: Is it justified? MoonLake trades on a P/B of 3.9x, which screens as expensive against the wider US biotechs industry but cheaper than its closer peer set. P/B compares a company’s market value to its net assets on the balance sheet. It is often used for early stage or loss making biotechs where earnings based metrics such as P/E are less useful. For MoonLake, the 3.9x P/B sits above the US biotechs industry average of 2.5x. This suggests the market is paying a premium to the sector for each dollar of book value. Against its more tightly defined peer group, where the average P/B is 9.8x, MoonLake’s multiple is materially lower. This indicates the market is attaching a smaller valuation to its assets than to similar names. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to book ratio of 3.9x (ABOUT RIGHT) However, you still need to weigh clinical trial risk around Sonelokimab, as well as the fact that MoonLake currently reports no revenue and a US$227.3 million net loss. Find out about the key risks to this MoonLake Immunotherapeutics narrative. Next Steps Curious whether the recent institutional interest and valuation picture justify the current price, or if risks still dominate the story? Act while sentiment is still forming by reviewing the company’s key pressure points, starting with these 3 important warning signs Looking for more investment ideas? Do not stop with a single stock when there is an entire market of opportunities waiting. Put a few minutes aside now to hunt for fresh ideas.  Target resilient income by reviewing companies in the 13 dividend fortresses that may help anchor your portfolio with higher yield potential. Hunt for quality at a discount using the 49 high quality undervalued stocks and see which names currently combine strong fundamentals with lower valuations. Spot quieter opportunities before they become crowded by scanning the screener containing 25 high quality undiscovered gems and checking which smaller names already show solid financial underpinnings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620738974","isCrawlerRequest":true}